![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 27, 24538-24545, July 5, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
,
,
,
,
From Departments of
Medicine and
§ Physiology, The Henry Wellcome Laboratory of Molecular and
Cellular Gastroenterology, University of Liverpool, Liverpool L69 3GA
and ¶ Department of Biochemistry, University of
Cambridge, 80 Tennis Court Rd., Cambridge
CB2 1GA, United Kingdom
Received for publication, April 12, 2002
| |
ABSTRACT |
|---|
|
|
|---|
Nuclear localization
sequence-dependent nuclear protein import is essential for
maintaining cell function and can be selectively blocked in epithelial
cells by mushroom (Agaricus bisporus) lectin. Here we
report that a major intracellular ligand for this lectin is an
N-terminally truncated form of oxygen-regulated protein 150 (Orp150), which lacks the endoplasmic reticulum
translocation signal peptide of full-length Orp150. This cytoplasmic
form of Orp150 expresses the lectin carbohydrate ligand
(sialyl-2,3-galactosyl- Nuclear compartmentation is one of the key features that
differentiate eukaryotic cells from prokaryotic cells. Genetic
information in the nucleus is separated from its cytoplasmic protein
regulators by the nuclear envelope. Molecular communication across the
nuclear envelope occurs through nuclear pore complexes and is essential for maintaining cell function and growth.
In previous studies, we demonstrate that a lectin (ABL) from the
common edible mushroom Agaricus bisporus, which recognizes the Thomsen-Friedenreich antigen (Gal The classical NLS-dependent nuclear protein import is to
date the best characterized nucleocytoplasmic transport pathway that mediates nuclear import of large proteins (>40-60 kDa) (6-8). The
classical NLS, which contains short stretches of basic amino acids, is
recognized by the "adapter" protein importin In the cytoplasm, conversion of RanGTP to RanGDP by GTPase-activating
protein (RanGAP1) and Ran-binding protein (RanBP1) results in
dissociation of the Ran-importin complexes and recycling of the carrier
importin molecules (12-14). RanGDP then transports back to the nucleus
after forming a complex with nuclear transport factor 2 (NTF2) (15-17)
and is converted back to RanGTP inside the nucleus (14, 18).
Thus, transport of cargo proteins requires three types of soluble
factors, transport receptor molecule (importin We have demonstrated in this study that one of the intracellular ABL
binding ligands is a truncated, hence cytoplasmically localized form of
oxygen-regulated protein 150 (Orp150) that is also shown to express the
ABL ligand,
sialyl-2,3-galactosyl- Materials--
Peroxidase-ABL, agarose-ABL, FITC-ABL, and
peroxidase-PNA were from EY Laboratories Inc. (San Mateo, CA).
Sialidase (EC 3.2.1.18) from Arthrobacter ureafaciens,
sialidase from Newcastle Disease virus (EC 3.2.1.18), and
O-glycanase (endo-
The human colon cancer cell line HT29 was obtained from the
European Cell Culture Collection at the Public Health
Laboratory Service, Porton Down, Wiltshire, UK and cultured in
Dulbecco's modified Eagle's medium containing 10% fetal calf serum,
100 units/ml of penicillin, 100 µg/ml streptomycin, and 4 mM glutamine. Cell culture medium was from Invitrogen.
Cytosolic Protein Extraction--
Confluent HT29 cells (6 × 108) were released by trypsinization from the cell
culture plates and washed 3 times with PBS. The cells (5 × 106) were suspended in PBS, and 10 µg/ml aprotinin
(Sigma) and leupeptin (Sigma) were added. The cells were sonicated 4 times for 25 s with 1-min intervals on salt-ice. The
unbroken cells, membranes, and debris were removed by centrifugation
(1000 × g for 5 min). The cytosolic proteins were
obtained after two centrifugations of the supernatant at 40,000 × g for 1 h at 4 °C. The protein concentration of the
extract was 1.2 mg/ml as determined by bicinchoninic acid method (20)
using a bicinchoninic acid solution kit (Sigma).
Affinity Purification of ABL Intracellular Binding
Ligands--
5 ml of ABL-agarose beads containing 7.5 mg of ABL (EY
Laboratories) were thoroughly washed with 50 ml of PBS before use. The
cytosolic protein extract was mixed with ABL-agarose beads by rotation
for 2 h at 4 °C. The beads were then poured into a column
(1 × 20 cm) and washed thoroughly with PBS till no protein was
detected in the eluate. Specific binding to ABL-agarose was released by
elution with 5 mM
galactose- SDS-Polyacrylamide Gel Electrophoresis, Lectin Blotting and
Immunoblotting--
SDS-polyacrylamide gel electrophoresis and protein
transfer to nitrocellulose or polyvinylidene difluoride membranes were performed as previously described (4). After application of peroxidase-conjugated lectins or the primary antibody followed by
peroxidase-conjugated secondary antibodies, bound proteins were
detected using a chemiluminescence immunoblotting detection kit
(Amersham Biosciences). The optical density of protein bands on immuno
and lectin blotting was analyzed using Quantity One software
(Bio-Rad).
N-terminal Protein Sequencing--
ABL-agarose affinity-purified
proteins were applied to SDS-polyacrylamide gel (7.5 or 10%)
electrophoresis running in the presence of 2 mM
thioglycollic acid in the upper electrode buffer to scavenge
N-blocking free radicals. After electrophoresis, the separated proteins were transferred to polyvinylidene
difluoride-Immobilon P (Sigma) membranes. The membrane was washed once
with distilled water and stained with 0.1% Coomassie Blue in 50%
methanol for 5 min. After destaining with 50% methanol, 10% acetic
acid, the membrane was washed again with distilled water and air-dried. The protein bands were sliced out and N-terminally sequenced using a
494 PROCISE protein sequencing system (Applied Biosystems, Warrington, UK) in the Protein and Nucleic Acid Facility of the Department of
Biochemistry, University of Cambridge.
Desialylation and Deglycosylation--
Equal amounts (0.2 µg)
of ABL-agarose affinity-purified proteins were incubated with or
without 1.5 units/ml A. ureafaciens sialidase (which cleaves
non-reducing terminal sialic acid Release of Cytoplasmic Orp150 by Digitonin
Treatment--
Release of cytoplasmic proteins was performed by
digitonin treatment under conditions that selectively release
cytoplasmic but not Golgi or endoplasmic reticulum proteins (43).
Subconfluent HT29 cells cultured in 6-well plates were treated with or
without 50 µg/ml digitonin in PBS for 5 min at 4 °C. The
supernatant and cells were recovered separately. Intact cells (4 × 104), digitonin-permeabilized cells(4 × 104), and the digitonin-released fractions (from 4 × 104 cells) were analyzed by SDS-PAGE (7.5%) and
immunoblotting using primary antibodies to Grp170, Hsp70 (Sigma), and
to the endoplasmic reticulum (ER) resident proteins ERp72 (BD
PharMingen) and protein disulfide isomerase (BD PharMingen)
followed by peroxidase-conjugated secondary antibodies (Dako, Denmark)
and detection by enhanced chemiluminescence.
Determination of Intracellular Co-localization of ABL and Orp150
by Confocal Microscopy--
To assess the localization of Orp150 and
ABL, subconfluent HT29 cells were cultured on glass coverslips in
Dulbecco's modified Eagle's medium containing 10% fetal calf serum
for 2 days. The medium was changed to serum-free medium (Dulbecco's
modified Eagle's medium containing 0.25 mg/ml BSA), and FITC-ABL (10 µg) was added. After 6 h at 37 °C, the cells were washed once
with culture medium, twice with PBS, and fixed with ethanol for 10 min
at -20 °C. The cells were then treated with 0.5% BSA, 0.5%
Triton-X-100, PBS, and 1% BSA, PBS each for 30 min at room
temperature. Anti-Grp170 antibody (1:500) in 1% BSA, PBS was then
applied for 1 h. After 4 washes with PBS, Texas Red conjugated
anti-rabbit antibody (1:50) in 1% BSA, PBS was applied for 1 h.
After extensive washes, the cells were mounted, and the subcellular
distributions of FITC and Texas Red were monitored simultaneously by
confocal microscopy (Noran Instruments Inc., Middleton, WI) with 60×
Nikon objective (1.4 NA) with excitation 488 nm and emission
500-560 nm for FITC and above 610 nm for Texas Red. Image
acquisition in slow mode (800 ns) was used with a slit of 25 µm, and
images were processed using TwoD Analysis software (Noran Instruments
Inc.).
Conjugation of NLS Peptide to BSA-FITC--
A peptide containing
the SV40 large T antigen wild type NLS CGGGPKKKRKVED was synthesized as
previously described (5). The NLS peptide was then conjugated to
BSA-FITC (Sigma) as previously described (5) with modification.
Briefly, 10 mg/ml BSA-FITC was activated by incubation with a 100-fold
molar excess of sulfo-SMCC (sulfosuccinimidyl
4-[N-maleimidomethyl] cyclohexane 1-carboxylate) (Pierce
and Warriner, Chester, UK) for 90 min at room temperature in 100 mM HEPES-NaOH (pH 7.3). Excess cross-linker was removed by
gel filtration on a PD10 column containing 9.1 ml of Sephadex-G25 (Amersham Biosciences). The activated BSA solution was reacted with a
30-fold molar excess of NLS peptide in 10 mM HEPES-NaOH (pH
7.5) for 2 h at 37 °C. Uncoupled peptide was removed by gel filtration on a PD10 column equilibrated in 150 mM NaCl.
The molar ratio of coupling was 15-25 peptides/BSA molecule as
estimated from the electrophoretic mobility.
Nuclear Import of NLS-BSA-FITC in Digitonin-permeabilized HT29
Cells--
Preparation of HT29 cell cytosol extracts for nuclear
protein import was performed as described previously (5). Cell
permeabilization and in vitro nuclear protein import was
carried out by a modification of the method previously described (5).
HT29 cells were cultured on glass coverslips inserted into 24-well cell
culture plates for 3 days in Dulbecco's modified Eagle's medium
containing 10% fetal calf serum. The cells were rinsed twice with PBS
and twice with cold transport buffer (20 mM HEPES-NaOH (pH
7.3), 110 mM potassium acetate, 5 mM sodium
acetate, 2 mM magnesium acetate, 1 mM EGTA, 2 mM dithiothreitol, 1 µg/ml aprotinin, and 1 µg/ml leupeptin) and then permeabilized by incubation with 40 µg
ml
For inhibition experiments, the cytosol extract was first incubated
with 100 µg/ml wheat germ agglutinin or anti-Grp170 antibody (1:100)
for 20 min at room temperature before mixing with the other transport
components and introduced to the digitonin-permeabilized cells.
Immunoprecipitation and Immunoabsorption--
100 µl of cell
cytosol extract (120 µg protein) obtained as described above was
"precleaned" by mixing with 10 µl of protein A-agarose beads
(Sigma) for 10 min. The beads were discarded after centrifugation at
16,000 × g for 3 min. The precleaned cytosol extract
was incubated with anti-Grp170 antibody (1:50) for 1 h before
introduction of 10 µl of protein A-agarose beads for another hour.
After centrifugation at 16,000 × g for 5 min, the
supernatant was kept as Orp150-depleted cytosol extract to be used in
nuclear transport. The immunoprecipitate was washed thoroughly with PBS and kept as Orp150 immunoprecipitate.
Affinity Purification of ABL Intracellular Binding
Ligands--
Using ABL-agarose affinity purification, eight cytosolic
proteins within the molecular mass range 46-300 kDa were obtained from
HT29 cytosolic protein extracts, of which the four lower molecular
weight proteins were stained strongly and the four higher molecular
weight proteins were stained weakly by Coomassie Blue (Fig.
1A). A lectin blot of the
eluate showed that only 4 of the 8 eluted proteins with molecular
weights of 90, 120, 160, and >250 kDa were directly recognized by ABL
peroxidase (Fig. 1B). The four proteins directly recognized
by ABL were those that stained weakly with Coomassie Blue (Fig.
1B).
To determine whether any of these proteins was a known cytoplasmic
transport factor, the apparent molecular sizes of the ABL-binding proteins were compared with those of the known transport factors. It
was clear that only the 90-kDa protein appeared to be close in size to
one of the known transport factors, importin Glycosylation Characterization of ABL Intracellular Binding
Ligands--
Our previous studies have shown that the ABL-mediated
effect on nuclear protein import is prevented by the addition of
glycoproteins that express the ABL carbohydrate ligand,
galactosyl-
It was found that none of the proteins eluted from ABL-agarose were
recognized by anti-TF-monoclonal antibody (Fig.
2A, first lane) or
by the TF binding PNA lectin (Figs. 2B and
2C, first lanes), suggesting the absence
of unsubstituted TF antigen on these intracellular proteins. To
determine whether any of the intracellular ABL-binding proteins might
express sialyl-TF antigen, the alternative carbohydrate binding ligand
of ABL (1-3), the eluate was treated with A. ureafaciens
sialidase to cleave sialic acid
Although A. ureafaciens sialidase removes sialic acid
whether Identification and Intracellular Localization of
Orp150--
Because the 160-kDa ABL-binding protein is the major
intracellular sialyl-TF-expressing glycoprotein (Fig. 2), this protein was selected for N-terminal sequencing. The sequence obtained, LAVMSVDLG, matched exactly with the 33-42-amino acid sequence of
oxygen-regulated protein 150 (Orp150), a member of the stress-related protein family that has more than 90% amino acid sequence identity with its hamster homologue glucose-regulated protein 170 (Grp170) (21).
The amino acids 33-426 of Orp150/Grp170 protein exhibit 32 and 30%
identity, respectively, with amino acids 1-380 of human and bovine
Hsp70 (21, 22), a heat-stress related protein directly involved in
NLS-dependent nuclear protein import (23-27). Immunoblot of the ABL affinity-purified proteins using a polyclonal antibody against Grp170 (Orp150) further supported Orp150 as the 160-kDa ABL-binding protein (Fig. 3A).
Immunoblotting with anti-Grp170 (Orp150) antibody confirms that
treatment with sialidase and O-glycanase induced
electrophoretic shifts, in keeping with expression of sialyl-TF by
Orp150 (Fig. 3B).
Orp150 is known as an ER-associated protein that is thought to function
as a molecular chaperone. Because the N-terminal 32 amino acids
represent the signal peptide for ER translocation (21, 28), the
discovery that ABL-purified Orp150 lacks this signal peptide suggests
that this may represent a free cytoplasmic form of Orp150 as predicted
by Kaneda et al. (28). Dual labeling of the cells with
FITC-ABL and anti-Grp170 antibody/Texas Red-conjugated second antibody
assessed by confocal microscopy revealed co-localization of ABL and
Orp150 in the cytoplasm, particularly in the perinuclear region (Fig.
4A). The existence of
cytoplasmic Orp150 is further demonstrated by digitonin treatment of
the cells under conditions that selectively release cytoplasmic but not
Golgi or ER resident proteins (43). Orp150, like Hsp70, is released
from the cells by digitonin treatment, whereas the typical ER-resident
proteins, Erp72 and protein disulfide isomerase, are not released by
this treatment (Fig. 4B).
Effect of Anti-Grp170 Antibody on Nuclear Localization of
NLS-BSA-FITC in Digitonin-permeabilized Cells--
Given the
cytoplasmic localization of the N-terminally truncated Orp150, its
expression of sialyl-TF, its co-localization with ABL, its sequence
similarity with nuclear transport factor Hsp70, and the known
inhibition of NLS-dependent nuclear import by ABL, we
speculated that Orp150 might be involved in NLS-dependent nuclear protein import. We therefore investigated the role of Orp150 in
nuclear protein import of a NLS-peptide complex (NLS-BSA-FITC) in
vitro in digitonin-permeabilized cells.
NLS-BSA-FITC accumulates in the nucleus in this transport system (Fig.
5A). Nuclear import of this
NLS complex was reduced by 53% (n = 3) by the presence
of wheat germ agglutinin (40 µg ml
To exclude the possibility that the inhibition of nuclear import by the
addition of anti-Grp170 antibody to the digitonin-permeabilized cells
might have be due to binding to ER-associated Orp150, NLS-BSA-FITC nuclear import was also investigated in the presence of free cytosolic Orp150-depleted cytosol extracts obtained by Orp150 immunoabsorption. As shown in Fig. 5B, more than
95% Orp150 was removed from the cytosol extracts by this
immunoabsorption process, whereas ER-associated Orp150, which remained
within the permeabilized cells, would not be affected by this process.
In the presence of these Orp150-free cytosol extracts, nuclear
accumulation of NLS-BSA-FITC was reduced by 41% (n = 3) (Fig. 5, A and C). To check that the
inhibition of NLS-BSA-FITC nuclear accumulation observed using
Orp150-depleted cytosol extracts was not due to loss during
immunoabsorption of the other known cytoplasmic nuclear transport
factors from the cytosol extracts, Orp150-depleted cytosol extracts
were assessed by immunoblotting using antibodies against the known
cytoplasmic nuclear transport factors. It was found that neither
importin Immunoprecipitation of Orp150 to Identify Its Possible Association
with Other Known Cytoplasmic Nuclear Transport Factors--
Having
demonstrated the involvement of Orp150 in NLS-dependent
nuclear import process, the possible association of Orp150 with the
other known cytoplasmic nuclear transport factors was investigated by
immunoprecipitation (Fig. 6). No importin The present studies show that Orp150, a highly diverged Hsp70-like
protein, has an N-terminal truncated form that is present in cytoplasm,
expresses sialyl-TF, and acts as a major ligand for ABL. Introduction
of anti-Orp150 antibody or depletion of Orp150 from the transport
system largely inhibited nuclear accumulation of NLS-BSA-FITC in
digitonin-permeabilized cells. This suggests that the truncated Orp150
functions as a cytosolic transport factor that is essential for the
NLS-dependent nuclear transport process.
The Orp150 protein family was first identified in Chinese hamster ovary
cells and termed glucose-regulated protein Grp170 (19). It has
subsequently been identified in rat (30) and human (21). Alignment of
the deduced amino acid sequences of human Orp150, rat Orp150, and
hamster Grp170 indicates greater than 91% identity (21), suggesting
that they are functionally homologous proteins. The N-terminal 33-426
amino acids of Orp150/Grp170 are 32% identical to the 1-380 amino
acids of both inducible human Hsp70 and constitutive bovine Hsp70 (21,
22). Its N-terminal 400 residues also contain an ATPase domain similar
to both Hsp70 and Hsp110 (22). The full-length Orp150 is an
ER-associated glycoprotein (19, 31) with a C-terminal ER retention
sequence of NDEF and an N-terminal ER-translocation sequence (21, 22). Induction of Orp150 expression has been demonstrated in human (32, 33)
and rat cells (30) by hypoxia and hypoglycemia but not by heat. The
physiological function of Orp150 is still not well understood. It has
been suggested that Orp150/Grp170 is involved in protein folding and
translocation into the endoplasmic reticulum (31, 34-37) and release
of proteins from the ER (38). Recently it has been reported that Orp150
plays a cytoprotective role in hypoxia-induced apoptosis in human
embryonic kidney cells (33) and hypoxia/ischemia-induced neuronal death
in human brain (39).
It is intriguing to find that a protein thought to be ER-associated
could be actively involved in nuclear translocation. The explanation of
this apparent paradox seems to be that cells also contain a cytosolic
form of Orp150. Recently Holaska et al. (43) discovered that
calreticulin, an ER-associated protein involved in protein folding (40,
41) and protection of nonglycosylated proteins from thermal
denaturation in the lumen of the ER (42), also has a cytoplasmic form
that acts as a receptor, mediating NES-related nuclear export by
forming an assembly with NES-protein and RanGTP. Although the presence
of cytosolic Orp150/Grp170 has not been reported before, Kaneda
et al. (28) recently cloned and sequenced the entire human
Orp150 gene and discovered three distinct Orp150 mRNAs produced by
alternative promoters. Analysis of transcription initiation sites and
transcriptional regulatory sequences revealed that two of the Orp150
mRNAs are started from exon 1 (1A and 1B), and the transcript
beginning from exon 1B is preferentially induced by hypoxia. The third
mRNA, which starts from alternative exon 2, was predicted to
produce a cytosolic protein lacking the N-terminal 32 amino acid ER
translocation signal peptide. In the present study, N-terminal protein
sequencing of ABL affinity-purified Orp150 has revealed just such a
truncated form of Orp150.
One property expected for a transport factor is its association, at
least at some stage during the transport process, with the other known
transport factors such as importins or the Ran protein family. The
discovery that Orp150 forms a complex inside cells with the small
GTPase Ran implies that Orp150 may be involved in the nuclear transport
process by interacting with Ran and perhaps has a role in the cycling
of Ran-GTP and Ran-GDP between the cytoplasm and nucleus that plays a
key role in controlling the directionality of nucleocytoplasmic
transport (10, 53).
During the last decade, evidence has accumulated to suggest that many
cytosolic and nuclear proteins are modified by glycosylation (44-46).
The best characterized intracellular glycosylation so far is
O-linked N-acetylglucosamine, which has been
found on many cytoplasmic and nuclear proteins such as transcription
factors, nucleoporins, cytoskeletal proteins, oncogene products, and
chromatin-associated proteins (44, 47). It has been suggested that
intracellular O-GlcNAc glycosylation, like phosphorylation,
may play an important role in many key cellular processes (44, 45, 47).
Other sugars, such as galactose, glucose, mannose,
N-acetylgalactosamine, and sialic acid, have been
occasionally reported on intracellular structures, usually demonstrated
by lectin binding (48). However, the cytoplasmic or nuclear
glycoconjugates that express these sugars have not been identified, and
in particular, no intracellular glycoproteins bearing
galactose-terminated or TF-expressing oligosaccharides have been
identified. The functional role of such O-linked
oligosaccharides is not known, and concealment of O-linked
GlcNAc on nucleoporin p62 by further extension with galactose has been
shown not to affect protein import (49). The functional role of
sialyl-TF expression by Orp150 glycoprotein in its role as a nuclear
transport protein is currently unclear. Duverger et al.
(50-52) suggest that sugars such as glucose, fucose-, mannose, or
N-acetylchitobiosides could serve as nuclear localization
signals and showed that glycoconjugates of BSA can move rapidly into
the nucleus. They have shown that, like the classical NLS-mediated
nuclear import, sugar-mediated nuclear import also requires energy and
is blocked by wheat germ lectin (51, 52). Unlike the classical NLS
pathway, however, this sugar-mediated nuclear import process has been
reported not to require cytosolic transport factors (51).
Orp150 thus seems to have at least two functions. The full-length
protein, which is targeted to the ER, serves as a stress protein
involved in cellular response to metabolic stress, whereas the
truncated protein, which is released into the cytoplasm, has a crucial
role in NLS-dependent nuclear protein import.
1,3-N-acetylgalactosamine-
) and is shown to be essential for nuclear localization
sequence-dependent nuclear protein import.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1,3GalNAc
) and its
sialylated form
(sialyl-2,3-galactosyl-
1,3-N-acetylgalactosamine-
)
(1-3), produces reversible inhibition of proliferation in a range of epithelial cells (4). The lectin has to be internalized to produce this
effect and selectively blocks the classical
NLS1-dependent
nuclear protein import (5). This implied that this lectin could be a
very useful tool in further elucidation of this system.
. Importin
(karyopherin
) binds to importin
(karyopherin
) (9), and the
cargo-importin complex then translocates into the nucleus through
nuclear pore complexes. The cargo-importin complex is then dissociated
by RanGTP (10), thus releasing the cargo from its carrier. Importin
then forms a trimeric complex with an importin
-related protein CAS
(cellular apoptosis susceptibility gene protein) (11) and RanGTP, and
this together with the importin
-RanGTP complex returns to the cytoplasm.
), adapter molecule
(importin
), and Ran and its binding proteins. Identification of
these soluble transport factors has largely been achieved using digitonin-permeabilized cells in which these factors have been shown to
be essential for nuclear protein import.
1,3-N-acetylgalactosamine-
. Introduction of an antibody against Grp170 (the hamster homologue of
Orp150) or depletion of Orp150 from the transport system by prior
immunoabsorption inhibited nuclear accumulation of NLS-bovine serum
albumin (BSA)-fluorescein isothiocyanate (FITC) in
digitonin-permeabilized cells. This suggests that the N-terminal
truncated form of Orp150 is essential for NLS-dependent
nuclear protein import.
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-N-acetylgalactosaminidase) (EC 3.2.1.97) from Streptococcus pneumoniae were obtained
from Oxford GlycoSciences (Abingdon, UK). Fluorescent mounting
medium was purchased from Vector Laboratories Inc. (Peterborough, UK). Anti-Orp150/Grp170 polyclonal antibody generated against purified Chinese hamster Grp170 in rabbit (19) was kindly provided by Dr. John
Subjeck from the Roswell Park Cancer Institute, Buffalo, New York.
1,3-N-acetylgalactosamine (Sigma) in the
presence of 15 mM EDTA. The eluate was then dialyzed thoroughly against PBS and freeze-dried.
2-3- or 2-6-linked to galactose,
N-acetylglucosamine, or N-acetylgalactosamine) for 20 h at 37 °C or 0.5 units/ml Newcastle Disease virus
sialidase (which cleaves non-reducing terminal sialic acid
2-3-linked to galactose or N-acetylgalactosamine) for
24 h at 37 °C in 10 mM sodium phosphate (pH 7.0).
Sialidase-treated or untreated eluates were further incubated with or
without 0.2 units/ml O-glycanase (endo-
-N-acetylgalactosaminidase) from S. pneumoniae (specific removal of Gal
1-3GalNAc) in 10 mM sodium citrate-phosphate (pH 6.0) for 24 h at
37 °C.
1 digitonin (Sigma) in transport buffer for 6 min at
4 °C. After 5 washes with ice-cold transport buffer, transport
mixture (final volume, 200 µl) was applied (20% cytosol fraction, 1 mM ATP, 5 mM creatine phosphate, 20 units/ml
creatine phosphokinase, 2 mM BSA-NLS-fluorescein in
transport buffer), and a protein transport reaction was allowed to
proceed for 45 min in a 30 °C incubator. Protein transport was
stopped by the addition of 1-ml of ice-cold transport buffer. After
extensive washes with ice-cold transport buffer, the slides were fixed
with ice-cold ethanol and mounted with Vectashield mounting medium
H-1000 (Vector). Intracellular fluorescein localization was
detected by fluorescence microscopy (Polyvar, Reichert-Jung,
Austria), and images were recorded using a Kodak DC120 digital camera
(Eastman Kodak Co.). Distribution of fluorescence in the nucleus and
cytoplasm was analyzed as described previously (5). Each experiment was
repeated at least three times with at least six randomly selected cells
analyzed on each occasion.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (43K):
[in a new window]
Fig. 1.
Intracellular ABL binding profile of HT29
cell cytosol extracts after ABL-agarose affinity purification.
A, Coomassie Blue staining shows that at least eight
proteins were eluted from the ABL-agarose column by Gal
1-3GalNAc.
B, lectin blotting of the eluate by peroxidase-ABL shows
that the four higher molecular weight proteins are directly recognized
by ABL. The gel and blot shown are typical examples from 1 of 10 purification procedures.
. However, immunoblotting using anti-importin
monoclonal antibody
(Transduction Laboratories Lexington, KY) indicated that this 90-kDa
intracellular protein obtained from ABL affinity purification was not
importin
(data not shown).
1,3-N-acetylgalactosamine-
, the
Thomsen-Friedenreich (TF) blood group antigen (4). This suggests that
the intracellular ABL-ligand interaction is mediated through
lectin-carbohydrate interactions. Therefore, to further identify the
functional intracellular ligand of ABL, we investigated the
glycosylation of the intracellular ABL-binding proteins obtained from
ABL affinity purification.
2-3-linked to galactose or 2-6 to
N-acetylgalactosamine. It was found that removal of sialic
acid residues resulted in strong binding of both anti-TF antibody (Fig.
2A, second lane) and PNA (Fig. 2B,
second lane) to the 160-kDa protein in addition to weak
binding to the 90- and >250-kDa proteins. Further treatment of the
sialidase-treated eluate with O-glycanase
(endo-
-N-acetylgalactosaminidase) to allow specific
removal of terminal Gal
1-3GalNAc
resulted in an 84% reduction
in binding of anti-TF antibody (Fig. 2A, third lane, and Fig. 2D) and a 62% reduction in binding of
PNA (Fig. 2B, third lane and Fig. 2E)
to the sialidase-treated 160-kDa protein. Weak binding to the 90- and
>250-kDa proteins by anti-TF antibody and PNA was also largely
inhibited by the sialidase treatment (Fig. 2). These results suggest
that the 90-, 160-, and >250-kDa intracellular proteins (but not the
120-kDa protein) are sialyl-TF antigen-expressing glycoproteins.

View larger version (38K):
[in a new window]
Fig. 2.
Determination of the nature of glycosylation
of the ABL ligands. The eluted proteins from ABL-agarose were
incubated without (A, B, C,
first lanes) or with sialidase from A. ureafaciens (A, B, second lanes)
to cleave terminal
2-3- or 2-6-linked sialic acid residues or
sialidase from Newcastle Disease virus (C, second
lane) to cleave terminal
2-3-linked sialic acid residues.
Sialidase-treated (A, B, C,
third lanes) or non-treated (A, B,
C, fourth lanes) eluates were further incubated
with O-glycanase from S. pneumoniae to allow
specific removal of Gal
1-GalNAc followed by anti-TF antibody
(A) or PNA (B and C) blotting. All
deglycosylation procedures were repeated at least once on different
samples with a similar result in each case. A, anti-TF
antibody blot shows no binding to any of the untreated eluted proteins
(first lane), strong binding to the 160-kDa protein after
A. ureafaciens sialidase treatment, decreased binding to
this protein after further treatment with O-glycanase
(third lane), and no binding after O-glycanase
treatment alone (fourth lane). B, PNA blot shows
results similar to anti-TF antibody, which are no binding to any of the
untreated eluted proteins (first lane), strong binding to
the 160-kDa protein after A. ureafaciens sialidase treatment
(second lane), decreased binding to this protein after
further treatment with O-glycanase (third lane),
and no binding after O-glycanase treatment alone
(fourth lane). C, PNA blot shows no binding to
any of the untreated eluted proteins (first lane), strong
binding to the 160- and >250-kDa proteins after Newcastle Disease
virus sialidase treatment, decreased binding to these proteins after
further treatment with O-glycanase (third lane),
and no binding after O-glycanase treatment alone
(fourth lane). These results suggest the presence of
sialyl-2,3-galactosyl-
1,3-N-acetylgalactosamine-
-R on
the 160- and >250-kDa proteins. Quantification of binding of anti-TF
(D) or PNA (E and F) to the 160-kDa
protein before and after sialidase (SA) and/or
O-glycanase treatments was estimated by scanning
densitometry.
2-3- or
2-6-linked to galactose or
N-acetylgalactosamine, it is known that ABL does not
recognize
galactosyl-
1,3-(sialyl2-6)-N-acetylgalactosamine-
(1-3). Moreover, PNA would be expected to bind
galactosyl-
1,3-(sialyl2-6)-N-acetylgalactosamine-
(2). Therefore these results suggest that the sialic acid on these
intracellular ABL-binding proteins is
2-3-linked to galactose. This
is confirmed by the following studies using sialidase from Newcastle
Disease virus that specifically cleaves non-reducing terminal
2-3-linked sialic acid residues. As shown in Fig. 2, treatment of
the eluate with sialidase from Newcastle Disease virus resulted in
strong binding of PNA to the 160- and >250-kDa proteins in addition to
weak binding to the 90-kDa protein (Fig. 2C, second
lane). Again, further treatment of the sialidase-treated eluate
with O-glycanase to allow specific removal of unsubstituted terminal Gal
1-3GalNAc resulted in a 73% reduction in binding of
PNA to the 160-kDa protein (Fig. 2C, third lane,
and 2F) as well as significantly decreased binding to the
90- and >250-kDa proteins. These results are in keeping with the
conclusion that these proteins express
sialyl-2,3-galactosyl-
1,3-N-acetylgalactosamine-
(sialyl-TF).

View larger version (30K):
[in a new window]
Fig. 3.
Identification of the 160-kDa ABL-binding
glycoprotein and its glycosylation by enzyme treatment and
immunoblotting. Immunoblotting of the ABL affinity eluate using
anti-Grp170 (Orp150) antibody confirms the identity of the 160-kDa
protein as Orp150 (A). After treatment with sialidase
(A. ureafaciens) (see legend of Fig. 2), Orp150 also showed
molecule shift in electrophoresis, further confirming its identity
(B).

View larger version (34K):
[in a new window]
Fig. 4.
Intracellular localization of Orp150 assessed
by confocal microscopy and digitonin treatment. A,
intracellular co-localization of ABL with Orp150 by confocal
microscopy. HT29 cells were incubated with FITC-ABL for 6 h before
being fixed and probed with anti-Grp170 antibody followed by Texas
Red-conjugated secondary antibody. Shown is co-localization
(yellow) of ABL (green) and Orp150
(red) in the perinuclear region (typical example from one of
three experiments). Bar, 10 µm. B, detection of
cytoplasmic proteins released by digitonin treatment. Lysed whole cells
(4 × 104), digitonin-permeabilized cells (4 × 104), or digitonin-released fractions from 4 × 104 cells were separated by electrophoresis followed by
immunoblotting using antibodies against Orp150, ERp72, protein
disulfide isomerase (PDI), and Hsp70. Orp150 and Hsp70 are
released by digitonin permeabilization, whereas the ER lumenal proteins
ERp72 and protein disulfide isomerase are not released.
1) (Fig. 5,
A and C), a lectin that has been shown previously
to block nuclear protein import by binding to
N-acetylglucosamine on p62 nucleoporin (29). The transport
process was also inhibited by 52% (n = 3) in the
absence of ATP (Fig. 5, A and C). Introduction of
an anti-Grp170 antibody to the transport system largely blocked the
nuclear accumulation of NLS-BSA-FITC (Fig. 5A), reducing the nuclear fluorescence by 57% (n = 5) (Fig.
5C). Introduction of irrelevant antibodies such as
anti-Erk1/2 antibody (Promega UK Ltd., Southampton, UK) (1:50) (not
shown) or normal rabbit serum (1:50) to the system did not show any
effect on the nuclear accumulation of NLS-BSA-FITC (Fig.
5A). Similar results were observed also in human gastric
cancer cell line AGS cells (not shown).

View larger version (53K):
[in a new window]
Fig. 5.
Effect of the addition of antibody against
Orp150 on nuclear accumulation of NLS-BSA-FITC in
digitonin-permeabilized HT29 cells. A, panel
1 shows NLS-BSA-FITC accumulated in the nucleus in the
presence of cytosol extracts and ATP regeneration system. NLS-BSA-FITC
nuclear accumulation was inhibited in the presence of wheat germ
agglutinin (WGA) (2) and in the absence of ATP
(3). Introduction of anti-Grp170 antibody (4) or
depletion of Orp150 from the cytosolic extracts by immunoabsorption
(5) both inhibited NLS-BSA-FITC nuclear accumulation. The
addition of irrelevant antibody or normal rabbit serum (6)
did not affect NLS-BSA-FITC nuclear accumulation. Each microphotograph
shows representative cells from one of three (2 and
3) and five (1, 4-6) experiments.
Bar, 10 µm. B, immunoabsorption of Orp150 from
the cytosol extract (from 100 µg of cytosol proteins) resulted in
Orp150-free cytosol extracts in which more than 95% Orp150 was removed
(b) compared with normal cytosol extracts (20 µg of
cytosol proteins) (a). Equivalent volumes of cytosol extract
(20 µl) were loaded in lanes a and b.
C, distribution of cellular fluorescence in the
nucleus and cytoplasm (n = 6 cells counted from 1 of 3 similar experiments).
, importin
, Hsp70, NTF2, nor Ran were significantly
decreased (less than 4%) in the Orp150-depleted cytosol extracts (data
not shown). These results indicate that the inhibition of nuclear accumulation of NLS-BSA-FITC observed above is due to loss of Orp150
from the transport system; hence, Orp150 is likely to be directly
involved in the NLS-dependent nuclear import process. The
lesser degree of inhibition of nuclear import (41 versus
57%) observed using Orp150-free cytosol extract compared with that which resulted from direct introduction of an anti-Grp170 antibody to
the system may be due to the presence of residual Orp150 remaining within the cells after permeabilization.

View larger version (31K):
[in a new window]
Fig. 6.
Immunoblots of Orp150 immunoprecipitates
using antibodies against various known cytoplasmic nuclear transport
factors. Shown are Orp150 immunoprecipitate (A-E,
lanes 2) (from 100 µg of cytosol protein) and control
cytosol extracts (A-E, lanes 1 (10 µg of
protein) and 3 (5 µg of protein) and F,
lane 5 (10 µg of protein). Panel A shows that
Orp150 was concentrated by the immunoprecipitation process. The dense
band at 60-70 kDa represents Grp170 antibody (A). Ran
(E), but not importin
(B), importin
(C), or Hsp70 (D), was also present in the Orp150
immunoprecipitates. Ran was also found in the eluate from the
ABL-agarose column (F, lane 4). Each blot is from
one of two similar experiments.
(Fig. 6B),
importin
(Fig. 6C), or Hsp70 (Fig. 6D) was
detected in the Orp150 immunoprecipitate. However, a small amount of
Ran (Fig. 6E) was found to be co-immunoprecipitated with
Orp150. This suggests that Orp150 may form a functional complex with
Ran inside cells. This is supported by the observation that ABL
affinity purification of the cell cytosol extracts, which pulls out
Orp150, also pulls out a small amount of Ran (Fig. 6F), as
identified by immunoblotting. To estimate the relative amount of Ran in
the Orp150 immunoprecipitate, optical density of the relevant bands was
quantified by densitometry. The Ran band in the Orp150
immunoprecipitate (from 100 µg of cytosolic extract proteins) was 10 times less dense than the Ran band in the control cytosol (10 µg of protein).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
| |
ACKNOWLEDGEMENT |
|---|
We are very grateful to Dr. John Subjeck (Roswell Park Cancer Institute, Buffalo, New York) for the anti-Grp170 antibody.
| |
FOOTNOTES |
|---|
* This work was supported by grants from the World Cancer Research Fund and North West Cancer Research Fund and by Medical Research Council Co-operative grant GR990432.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed. Tel.:
44-51-706-4073; Fax: 44-151-706-5802; E-mail:
rhodesjm@liv.ac.uk.
Published, JBC Papers in Press, April 17, 2002, DOI 10.1074/jbc.M203550200
| |
ABBREVIATIONS |
|---|
The abbreviations used are: NLS, nuclear localization sequence; BSA, bovine serum albumin; FITC, fluorescein isothiocyanate; PBS, phosphate-buffered saline; ER, endoplasmic reticulum; TF, Thomsen-Friedenreich; Orp150, oxygen-regulated protein 150; Grp170, glucose-regulated protein 170; ABL, Agaricus bisporus lectin; PNA, peanut agglutinin.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Presant, C. A., and Kornfeld, S. (1972) J. Biol. Chem. 247, 6837-6945 |
| 2. | Chen, Y., Jain, R. K., Chandrasekaran, E. V., and Matta, K. L. (1995) Glycoconj. J. 12, 55-62[CrossRef][Medline] [Order article via Infotrieve] |
| 3. | Sueyoshi, S., Tsuji, T., and Osawa, T. (1988) Carbohydr. Res. 178, 213-224[CrossRef][Medline] [Order article via Infotrieve] |
| 4. |
Yu, L.,
Fernig, D. G.,
Smith, J. A.,
Milton, J. D.,
and Rhodes, J. M.
(1993)
Cancer Res.
53,
4627-4632 |
| 5. |
Yu, L. G.,
Fernig, D. G.,
White, M. R. H.,
Spiller, D. G.,
Evans, R. C.,
Appleton, P.,
Grierson, I.,
Smith, J. A.,
Davies, H.,
Gerasimenko, O. V.,
Petersen, O. H.,
Milton, J. D.,
and Rhodes, J. M.
(1999)
J. Biol. Chem.
274,
4890-4899 |
| 6. | Mattaj, I. W., and Englmeier, L. (1998) Annu. Rev. Biochem. 67, 265-306[CrossRef][Medline] [Order article via Infotrieve] |
| 7. | Adam, S. A. (1999) Curr. Opin. Cell Biol. 11, 402-406[CrossRef][Medline] [Order article via Infotrieve] |
| 8. | Nakielny, S., and Dreyfuss, G. (1999) Cell 99, 677-690[CrossRef][Medline] [Order article via Infotrieve] |
| 9. | Gorlich, D., Henklein, P., Laskey, R. A., and Hartmann, E. (1996) EMBO J. 15, 1810-1817[Medline] [Order article via Infotrieve] |
| 10. | Gorlich, D., Pante, N., Kutay, U., Aebi, U., and Bischoff, F. R. (1996) EMBO J. 15, 5584-5594[Medline] [Order article via Infotrieve] |
| 11. | Kutay, U., Bischoff, F. R., Kostka, S., Kraft, R., and Gorlich, D. (1997) Cell 90, 1061-1071[CrossRef][Medline] [Order article via Infotrieve] |
| 12. | Coutavas, E., Ren, M., Oppenheim, J. D., D'Eustachio, P., and Rush, M. G. (1993) Nature 366, 585-587[CrossRef][Medline] [Order article via Infotrieve] |
| 13. | Bischoff, F. R., Krebber, H., Smirnova, E., Dong, W., and Ponstingl, H. (1995) EMBO J. 14, 705-715[Medline] [Order article via Infotrieve] |
| 14. |
Takai, Y.,
Sasaki, T.,
and Matozaki, T.
(2001)
Physiol. Rev.
81,
153-208 |
| 15. | Ribbeck, K., Lipowsky, G., Kent, H. M., Stewart, M., and Gorlich, D. (1998) EMBO J. 17, 6587-6598[CrossRef][Medline] [Order article via Infotrieve] |
| 16. |
Steggerda, S. M.,
Black, B. E.,
and Paschal, B. M.
(2000)
Mol. Biol. Cell
11,
703-719 |
| 17. |
Quimby, B. B.,
Lamitina, T.,
L'Hernault, S. W.,
and Corbett, A. H.
(2000)
J. Biol. Chem.
275,
28575-28582 |
| 18. | Dasso, M. (2001) Cell 104, 321-324[CrossRef][Medline] [Order article via Infotrieve] |
| 19. | Lin, H. Y., Masso-Welch, P., Di, Y. P., Cai, J. W., Shen, J. W., and Subjeck, J. R. (1993) Mol. Biol. Cell 4, 1109-1119[Abstract] |
| 20. | Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Anal. Biochem. 150, 76-85[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Ikeda, J., Kaneda, S., Kuwabara, K., Ogawa, S., Kobayashi, T., Matsumoto, M., Yura, T., and Yanagi, H. (1997) Biochem. Biophys. Res. Commun. 230, 94-99[CrossRef][Medline] [Order article via Infotrieve] |
| 22. | Chen, X., Easton, D., Oh, H. J., Lee-Yoon, D. S., Liu, X, and Subjeck, J. (1996) FEBS Lett. 380, 68-72[CrossRef][Medline] [Order article via Infotrieve] |
| 23. |
Shi, Y.,
and Thomas, J. O.
(1992)
Mol. Cell. Biol.
12,
2186-2192 |
| 24. |
Imamoto, N.,
Matsuoka, Y.,
Kurihara, T.,
Kohno, K.,
Miyagi, M.,
Sakiyama, F.,
Okada, Y.,
Tsunasawa, S.,
and Yoneda, Y.
(1992)
J. Cell Biol.
119,
1047-1061 |
| 25. |
Yang, J.,
and DeFranco, D. B.
(1994)
Mol. Cell. Biol.
14,
5088-5098 |
| 26. |
Shulga, N.,
Roberts, P., Gu, Z.,
Spitz, L.,
Tabb, M. M.,
Nomura, M.,
and Goldfarb, D. S.
(1996)
J. Cell Biol.
135,
329-339 |
| 27. |
Saphire, A. C.,
Guan, T.,
Schirmer, E. C.,
Nemerow, G. R.,
and Gerace, L.
(2000)
J. Biol. Chem.
275,
4298-4304 |
| 28. |
Kaneda, S.,
Yura, T.,
and Yanagi, H.
(2000)
J. Biochem. (Tokyo)
128,
529-538 |
| 29. |
Finlay, D. R.,
Newmeyer, D. D.,
Price, T. M.,
and Forbes, D. J.
(1987)
J. Cell Biol.
104,
189-200 |
| 30. |
Kuwabara, K.,
Matsumoto, M.,
Ikeda, J.,
Hori, O.,
Ogawa, S.,
Maeda, Y.,
Kitagawa, K.,
Imuta, N.,
Kinoshita, T.,
Stern, D. M.,
Yanagi, H.,
and Kamada, T.
(1996)
J. Biol. Chem.
271,
5025-5032 |
| 31. | Spee, P., Subjeck, J., and Neefjes, J. (1999) Biochemistry 38, 10559-10566[CrossRef][Medline] [Order article via Infotrieve] |
| 32. | Tsukamoto, Y., Kuwabara, K., Hirota, S., Kawano, K., Yoshikawa, K., Ozawa, K., Kobayashi, T., Yanagi, H., Stern, D. M., Tohyama, M., Kitamura, Y., and Ogawa, S. (1998) Lab. Invest. 78, 699-706[Medline] [Order article via Infotrieve] |
| 33. |
Ozawa, K.,
Kuwabara, K.,
Tamatani, M.,
Takatsuji, K.,
Tsukamoto, Y.,
Kaneda, S.,
Yanagi, H.,
Stern, D. M.,
Eguchi, Y.,
Tsujimoto, Y.,
Ogawa, S.,
and Tohyama, M.
(1999)
J. Biol. Chem.
274,
6397-6404 |
| 34. | Dierks, T., Volkmer, J., Schlenstedt, G., Jung, C., Sandholzer, U., Zachmann, K., Schlotterhose, P., Neifer, K., Schmidt, B., and Zimmermann, R. (1996) EMBO J. 15, 6931-6942[Medline] [Order article via Infotrieve] |
| 35. |
Saris, N.,
Holkeri, H.,
Craven, R. A.,
Stirling, C. J.,
and Makarow, M.
(1997)
J. Cell Biol.
137,
813-824 |
| 36. |
Kuznetsov, G.,
Chen, L. B.,
and Nigam, S. K.
(1997)
J. Biol. Chem.
272,
3057-3063 |
| 37. | Bando, Y., Ogawa, S., Yamauchi, A., Kuwabara, K., Ozawa, K., Hori, O., Yanagi, H., Tamatani, M., and Tohyama, M. (2000) Am. J. Physiol. Cell. Physiol. 278, 1172-1182 |
| 38. | Ozawa, K., Kondo, T., Hori, H., Kitao, Y., Stern, D. M., Eisenmenger, W., Ogawa, S., and Ohshima, T. (2001) J. Clin. Invest. 108, 41-50[CrossRef][Medline] [Order article via Infotrieve] |
| 39. | Tamatani, M., Matsuyama, T., Yamaguchi, A., Mitsuda, N., Tsukamoto, Y., Taniguchi, M., Che, Y. H., Ozawa, K., Hori, O., Nishimura, H., Yamashita, A., Okabe, M., Yanagi, H., Stern, D. M., Ogawa, S., and Tohyama, M. (2001) Nat. Med. 7, 317-323[CrossRef][Medline] [Order article via Infotrieve] |
| 40. | Krause, K. H., and Michalak, M. (1997) Cell 88, 439-443[CrossRef][Medline] [Order article via Infotrieve] |
| 41. | Vassilakos, A., Michalak, M., Lehrman, M. A., and Williams, D. B. (1998) Biochemistry 37, 3480-3490[CrossRef][Medline] [Order article via Infotrieve] |
| 42. | Saito, Y., Ihara, Y., Leach, M. R., Cohen-Doyle, M. F., and Williams, D. B. (1999) EMBO J. 18, 6718-6729[CrossRef][Medline] [Order article via Infotrieve] |
| 43. |
Holaska, J. M.,
Black, B. E.,
Love, D. C.,
Hanover, J. A.,
Leszyk, J.,
and Paschal, B. M.
(2001)
J. Cell Biol.
152,
127-140 |
| 44. | Hart, G. W. (1997) Annu. Rev. Biochem. 66, 315-335[CrossRef][Medline] [Order article via Infotrieve] |
| 45. |
Wells, L.,
Vosseller, K.,
and Hart, G. W.
(2001)
Science
291,
2376-2378 |
| 46. |
Helenius, A.,
and Aebi, M.
(2001)
Science
291,
2364-2369 |
| 47. |
Comer, F. I,
and Hart, G. W.
(2000)
J. Biol. Chem.
275,
29179-29182 |
| 48. | Hart, G. W. (1999) in Essentials of Glycobiology (Varki, A. , Cummings, R. , Esko, J. , Freeze, H. , Hart, G. , and Marth, J., eds) , pp. 171-182, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY |
| 49. |
Miller, M. W.,
and Hanover, J. A.
(1994)
J. Biol. Chem.
269,
9289-9297 |
| 50. | Duverger, E., Carpentier, V., Roche, A. C., and Monsigny, M. (1993) Exp. Cell Res. 207, 197-201[CrossRef][Medline] [Order article via Infotrieve] |
| 51. | Duverger, E., Pellerin-Mendes, C., Mayer, R., Roche, A. C., and Monsigny, M. (1995) J. Cell Sci. 108, 1325-1332[Abstract] |
| 52. |
Duverger, E.,
Roche, A. C.,
and Monsigny, M.
(1996)
Glycobiology
6,
381-386 |
| 53. | Izaurralde, E., Kutay, U., von Kobbe, C., Mattaj, I. W., and Gorlich, D. (1997) EMBO J. 16, 6535-6547[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
D. D. Arrington and R. G. Schnellmann Targeting of the molecular chaperone oxygen-regulated protein 150 (ORP150) to mitochondria and its induction by cellular stress Am J Physiol Cell Physiol, February 1, 2008; 294(2): C641 - C650. [Abstract] [Full Text] [PDF] |
||||
![]() |
L.-G. Yu, N. Andrews, Q. Zhao, D. McKean, J. F. Williams, L. J. Connor, O. V. Gerasimenko, J. Hilkens, J. Hirabayashi, K. Kasai, et al. Galectin-3 Interaction with Thomsen-Friedenreich Disaccharide on Cancer-associated MUC1 Causes Increased Cancer Cell Endothelial Adhesion J. Biol. Chem., January 5, 2007; 282(1): 773 - 781. [Abstract] [Full Text] [PDF] |
||||